We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+0.14%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$204M
AUM Growth
+$15.9M
Cap. Flow
+$17.5M
Cap. Flow %
8.58%
Top 10 Hldgs %
6.14%
Holding
488
New
66
Increased
245
Reduced
135
Closed
40

Top Buys

Rank Stock Value
1
QCOM icon
Qualcomm
QCOM
+$976K
2
NFLX icon
Netflix
NFLX
+$953K
3
CRWD icon
CrowdStrike
CRWD
+$952K
4
RCL icon
Royal Caribbean
RCL
+$905K
5
TJX icon
TJX Companies
TJX
+$890K

Top Sells

Rank Stock Value
1
PXD
Pioneer Natural Resource Co.
PXD
+$1.11M
2
LLY icon
Eli Lilly
LLY
+$937K
3
FCX icon
Freeport-McMoran
FCX
+$933K
4
ALGN icon
Align Technology
ALGN
+$933K
5
MLM icon
Martin Marietta Materials
MLM
+$930K

Sector Composition

Rank Sector Weight
1 Financials 26.66%
2 Healthcare 19.14%
3 Technology 17.16%
4 Energy 7.21%
5 Industrials 6.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADMA icon
201
ADMA Biologics
ADMA
$1.92B
$342K 0.17%
30,552
-63,760
-68% -$535K
LGND icon
202
Ligand Pharmaceuticals
LGND
$6.02B
$341K 0.17%
4,049
-1,579
-28% -$126K
EXEL icon
203
Exelixis
EXEL
$13.9B
$337K 0.17%
14,998
-1,348
-8% -$29.9K
LEGN icon
204
Legend Biotech
LEGN
$4.3B
$334K 0.16%
7,542
+1,335
+22% +$61.6K
HRMY icon
205
Harmony Biosciences
HRMY
$2.04B
$334K 0.16%
11,067
-213
-2% -$6.41K
BPMC
206
DELISTED
Blueprint Medicines
BPMC
$334K 0.16%
3,096
-1,450
-32% -$145K
MDGL icon
207
Madrigal Pharmaceuticals
MDGL
$12.6B
$333K 0.16%
1,189
+821
+223% +$195K
NBIX icon
208
Neurocrine Biosciences
NBIX
$17.7B
$333K 0.16%
2,417
-723
-23% -$99.2K
KRYS icon
209
Krystal Biotech
KRYS
$9.88B
$331K 0.16%
1,802
+1,058
+142% +$178K
YMAB
210
DELISTED
Y-mAbs Therapeutics
YMAB
$330K 0.16%
+27,332
New +$369K
ITCI
211
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$330K 0.16%
4,814
-1,019
-17% -$70.7K
KNSA icon
212
Kiniksa Pharmaceuticals
KNSA
$4.83B
$328K 0.16%
17,556
-4,791
-21% -$89.8K
BCRX icon
213
BioCryst Pharmaceuticals
BCRX
$2.37B
$327K 0.16%
52,865
-6,392
-11% -$35.3K
BIIB icon
214
Biogen
BIIB
$29.9B
$326K 0.16%
1,408
-78
-5% -$17K
TBPH icon
215
Theravance Biopharma
TBPH
$874M
$326K 0.16%
38,386
+3,779
+11% +$34.1K
ROIV icon
216
Roivant Sciences
ROIV
$25.2B
$322K 0.16%
30,467
-3,766
-11% -$41.3K
BMRN icon
217
BioMarin Pharmaceuticals
BMRN
$11.5B
$322K 0.16%
3,910
+6
+0.2% +$500
INCY icon
218
Incyte
INCY
$23.5B
$318K 0.16%
5,254
-715
-12% -$40.5K
SWTX
219
DELISTED
SpringWorks Therapeutics
SWTX
$317K 0.16%
8,415
-2,572
-23% -$108K
RARE icon
220
Ultragenyx Pharmaceutical
RARE
$2.65B
$314K 0.15%
7,638
-661
-8% -$28.2K
IOVA icon
221
Iovance Biotherapeutics
IOVA
$2.23B
$313K 0.15%
39,069
+27,832
+248% +$298K
SAGE
222
DELISTED
Sage Therapeutics
SAGE
$311K 0.15%
28,639
+10,674
+59% +$137K
PHAT icon
223
Phathom Pharmaceuticals
PHAT
$912M
$310K 0.15%
30,078
+20,377
+210% +$210K
DVAX
224
DELISTED
Dynavax Technologies
DVAX
$308K 0.15%
27,423
+21,041
+330% +$245K
FOLD
225
DELISTED
Amicus Therapeutics
FOLD
$307K 0.15%
30,939
+335
+1% +$3.44K
7 8
9
10 11

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
ALS
Andrew L. Share $214M AUM 14.75% 1-Year Est. Return

Virtus ETF Advisers's Q2 2024 Portfolio in Review

As of Q2 2024, Virtus ETF Advisers held 488 positions worth $204M, up 8.5% from $188M the previous quarter. Its ten largest holdings account for 6.1% of the portfolio.

Virtus ETF Advisers deployed $17.5M of net new capital in Q2 2024, opening 66 new positions and adding to 245 existing holdings. Its largest new stake was Qualcomm: 5,165 shares worth $1.03M.

By sector, the portfolio is most concentrated in Financials at 27% of assets, up from 20% a quarter earlier, followed by Healthcare and Technology.

On the sell side, the largest reduction was Extra Space Storage, an estimated $732K trimmed.

  • Virtus ETF Advisers's largest Q2 2024 buy was Qualcomm: 5,165 shares worth $1.03M.
  • Virtus ETF Advisers added most to EOG Resources in Q2 2024, an estimated $789K increase.
  • Virtus ETF Advisers's biggest Q2 2024 reduction was Extra Space Storage, cutting an estimated $732K.
  • Virtus ETF Advisers fully exited Pioneer Natural Resource Co. in Q2 2024, selling an estimated $1.11M.
  • Virtus ETF Advisers's ten largest holdings make up 6.1% of its $204M portfolio in Q2 2024.
  • Virtus ETF Advisers opened 66 new positions and closed 40 in Q2 2024.
  • Virtus ETF Advisers's portfolio value rose 8.5% quarter-over-quarter to $204M.

Based on Virtus ETF Advisers's 13F filing for Q2 2024, filed 14 Aug 2024.